ALN1003 Yields Significant Body-Fat-Adjusted Liver Weight Drop in 48-Day DIO Mice
TCRT•In a 48-day diet-induced obesity mouse study, ALN1003-treated animals had significantly lower liver weight after adjustment for body fat percentage (ANCOVA p=0.000005; HC3 p=0.000015). This finding aligns with prior reductions in liver-injury enzymes, mean NAFLD Activity Scores, and HOMA-IR, supporting further preclinical evaluation of ALN1003’s metabolic and liver-related effects.
1. Preclinical Study Results
In a 48-day non-GLP diet-induced obesity mouse study, ALN1003-treated animals exhibited significantly lower liver weight after adjusting for body fat percentage (ANCOVA p=0.000005; HC3 p=0.000015). Findings were directionally consistent with a 43% absolute liver weight reduction, lower ALT, AST, ALP, reduced NAFLD Activity Scores, and decreased HOMA-IR.
2. Context and Next Steps
These body-fat-adjusted liver-weight results align with earlier data showing improved adipose endocrine biomarkers, including higher adiponectin and lower leptin ratios. Limitations include small sample size, post hoc analysis, and non-GLP design; the company plans further controlled preclinical studies to evaluate formulation, exposure-response, tolerability, and liver biology in metabolic disease contexts.
